# Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

> **NCT02253654** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 216 (actual)

## Conditions studied

- Renal Insufficiency, Chronic
- Anemia
- Renal Dialysis
- Erythrocyte Transfusion

## Interventions

- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT02253654
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-01
- **Primary completion:** 2016-04-27
- **Final completion:** 2016-05-25
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02253654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02253654, "Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02253654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*